A health ministry panel is questioning Novartis Pharma K.K.'s use of clinical research data in promoting the sale of Diovan, its drug to lower blood pressure, saying it "could constitute misleading advertisement" after revelations that some of the data were manipulated. The Japanese unit of ...
Novartis ordered to state skin disorders as Diovan side effects
The health ministry has instructed Novartis Pharma K.K. to state in an attached note for its Diovan blood pressure-lowering drug that the medicine may cause serious skin disorders. Diovan, whose generic name is valsartan, has been cited in a recent suspected case of clinical data ...
A Kyoto university's announcement that research on blood-pressure drug Diovan was manipulated raises concerns about the drugmaker's objectivity.
Markets flunk challenge of poor people's health
A lack of balance exists between the health needs of really poor people in the world and the market for helping the rich and super-rich lead a fashionable lifestyle.
